Continuously monitoring more than 50,000 news publishers worldwide each day and analysing conversations across a global ...

Parul University held its ninth convocation ceremony today, Monday, December 22, where more than 16,000 students from the class of 2025 graduated. The ceremony ...

Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

A professional jockey has swapped the racecourse for the research lab, mastering neuroscience to help find ground-breaking ...

The Dreaming Prince in Ecstasy is one of 2025’s most striking extreme-metal releases. Not just because it blends black metal with psychedelic tones reminiscent of David Bowie, but because it plays ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minuteAvailability of Lunsumio VELO allows treatment aligned to people’s clinical needs and personal preferences Approval ...

Detailed price information for Adyton Resources Corp (ADY-X) from The Globe and Mail including charting and trades.

I am accused of being a global funds manager masquerading as a journalist. Facts don't matter much in a war of disinformation waged agains renewables.

New findings from the 2025 UK StartUp Report reveal that the UK is an entrepreneurial nation with founders launching businesses faster than ever ...

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada ...

The Epilepsy Foundation of America (EFA), in partnership with the Danny Did Foundation, announced Lampsy Health as the winner ...